My theory, once more, is that they want to keep it down so they get the delisting notice, making shareholders feel obligated to vote yes for another r/s, which in turn will allow the company to exercise the series D warrants, freeing them to grow for the remainder of what could be a big 2016.
You are correct with your play. Take profit on an FDA pop, get back in when the r/s dust settles....Profit!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.